# A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

> **NCT07723833** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 152 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Elecoglipron Reference Formulation Dose A
- **DRUG:** Elecoglipron Test formulation 1 Dose A
- **DRUG:** Elecoglipron Reference Formulation Dose B
- **DRUG:** Elecoglipron Test formulation 1 Dose B
- **DRUG:** Elecoglipron Test formulation 2 Dose A
- **DRUG:** Elecoglipron Test formulation 2 Dose B

## Key facts

- **NCT ID:** NCT07723833
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2026-11-18
- **Final completion:** 2026-11-18
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723833, "A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*